肝胆相照论坛

标题: REPLICor publishes the initial pre-clinical development of its NAP technology [打印本页]

作者: tonychant    时间: 2014-1-25 21:56     标题: REPLICor publishes the initial pre-clinical development of its NAP technology

Montreal, Quebec – November 2013 – Two papers detailing the initial pre-clinical development of REPLICor’s NAP technology for the treatment of chronic HBV infection were published in the November 2013 (Volume 57) edition of the journal Antimicrobial Agents and Chemotherapy.  These papers cover the initial in vitro and in vivo studies done with NAP compounds in collaboration with the lab of Dr. Allison Jilbert at the University of Adelaide, Adelaide, Australia and describe the optimized NAP REP 2055 (REP 9AC) which was first used to treat human patients.
作者: StephenW    时间: 2014-1-25 22:56

Serendipity of Science科学的运气:

核酸聚合物防范,建立鸭乙型肝炎病毒感染的体内

    Faseeha Noordeena , B,
    安德鲁Vaillantc和
    艾里逊河Jilberta

+作者所属机构

    分子与生物医学科学,阿德莱德大学,阿德莱德, Australiaa学院
    微生物学,医学系,佩勒代尼耶大学,斯里兰卡Lankab系
    REPLICor公司,蒙特利尔,魁北克, Canadac

摘要

核酸聚合物( NAP)的是使用硫代磷酸酯寡核苷酸(PS- ONS)的顺序无关的属性作为两亲性聚合物,以阻断参与病毒进入两亲性相互作用新颖,广谱抗病毒化合物。利用鸭乙型肝炎病毒( DHBV )模型人体感染乙肝病毒的,国家行动方案已被证明有两个入口和体外初级鸭肝细胞( PDH )后补的抗病毒活性乙型肝炎病毒感染。

核酸聚合物抑制鸭乙型肝炎病毒感染体外

    Faseeha Noordeen a ,b,
    安德鲁Vaillant c
    艾里逊河Jilbert a

+作者所属机构

   a 分子与生物医学科学,阿德莱德大学,阿德莱德, Australia
   b 微生物学,医学系,佩勒代尼耶大学,斯里兰卡Lanka
   c  REPLICor公司,蒙特利尔,魁北克, Canada

摘要

核酸聚合物( NAP)的利用硫代磷酸酯寡核苷酸( PS- ONS )的序列无关的特性主要针对参与病毒复制蛋白相互作用。国家行动方案广泛活跃反对使用I型进入机制包膜病毒多元化..........
在体外对乙型肝炎病毒国家行动方案的抗病毒活性严格依赖于他们的两亲性质,这表明国家行动方案,两亲性目标(s) ,这对于需要感染乙型肝炎病毒进入和后补机制的重要互

Nucleic Acid Polymers Prevent the Establishment of Duck Hepatitis B Virus Infection In Vivo

    Faseeha Noordeen a,b,
    Andrew Vaillantc c
    Allison R. Jilbert a

+ Author Affiliations

  a  School of Molecular and Biomedical Science, University of Adelaide, Adelaide, Australiaa
  b  Department of Microbiology, Faculty of Medicine, University of Peradeniya, Sri Lankab
  c  REPLICor Inc., Montreal, Quebec, Canadac

ABSTRACT

Nucleic acid polymers (NAPs) are novel, broad-spectrum antiviral compounds that use the sequence-independent properties of phosphorothioate oligonucleotides (PS-ONs) as amphipathic polymers to block amphipathic interactions involved in viral entry. Using the duck hepatitis B virus (DHBV) model of human hepatitis B virus infection, NAPs have been shown to have both entry and postentry antiviral activity against DHBV infection in vitro in primary duck hepatocytes (PDH).

Nucleic Acid Polymers Inhibit Duck Hepatitis B Virus Infection In Vitro

    Faseeha Noordeena,b,
    Andrew Vaillantc and
    Allison R. Jilberta

+ Author Affiliations

    School of Molecular and Biomedical Science, University of Adelaide, Adelaide, Australiaa
    Department of Microbiology, Faculty of Medicine, University of Peradeniya, Sri Lankab
    REPLICor Inc., Montreal, Quebec, Canadac

ABSTRACT

Nucleic acid polymers (NAPs) utilize the sequence-independent properties of phosphorothioate oligonucleotides (PS-ONs) to target protein interactions involved in viral replication. NAPs are broadly active against a diverse range of enveloped viruses that use type I entry mechanisms..........
The antiviral activity of NAPs against DHBV in vitro was strictly dependent on their amphipathic character, suggesting that NAPs interact with amphipathic target(s) that are important for DHBV entry and postentry mechanisms required for infection.

作者: 咬牙硬挺    时间: 2014-1-28 21:18

还有进展啊,继续关注




欢迎光临 肝胆相照论坛 (http://hbvhbv.info/forum/) Powered by Discuz! X1.5